BluSense Diagnostics announced as the winner of the prestigious Nordic Stars 2018 Award

BluSense Diagnostics has been the only Danish company honoured with the Nordic Stars 2018 Award. This distinction is awarded for the outstanding innovation and entrepreneurial skills demonstrated in developing a point-of-care platform for the diagnosis of life-threatening diseases. The ceremony took place at the end of the Nordic Life Science Days in Stockholm yesterday, September 12th.

“It is a great honour to be recognised for our success in developing an affordable and accurate blood testing platform for dengue fever. It is a great recognition for the hard work that our engineers and scientists, in Denmark and Taiwan, have dedicated to the launch of our first product”, - declared on stage Filippo Bosco, CEO, BluSense Diagnostics.

“BluSense Diagnostics has shown great determination, developing an innovative point-of-care platform for accurate, portable and affordable infectious disease diagnostics in four years. After receiving CE marking and EU grant this year, we are looking forward to following the commercial launch of their first diagnostic test for acute dengue fever”, - noted Björn Ursing, Chairman of the Nordic Stars Award.

This year, BluSense Diagnostics has reached a major milestone by obtaining CE-marking for their reader (BluBox) and diagnostic test for acute dengue fever (ViroTrack Acute). BluSense has also been awarded EUR 2M under the Horizon 2020 SME phase II grant for expanding its product portfolio and bringing new tests to the market.

About BluSense: 
BluSense was founded in 2014 as a spin-off from the Technical University of Denmark (DTU). It is a global-born start-up with operations in Denmark and Taiwan. The BluSense platform is built around its core IP, a novel immunoassay detection technology based on the use of nanoparticles and low-cost, mass-production compatible electronics of Blu-Ray players.